Login to Your Account



Pfizer Update

Remoxy on the Rocks: Durect, Pain Therapeutics Stocks Sink

By Catherine Shaffer
Staff Writer

Monday, May 13, 2013
In a footnote to its recent 10-Q filing, Pfizer Inc. shared results of a March meeting with the FDA to discuss a June 2011 complete response letter (CRL) for Remoxy (oxycodone) saying that it may not continue development, and if so, it would not have a response to the CRL before mid-2015.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription